Tracking Devices for Pets: Health Risk Assessment for Exposure to Radiofrequency Electromagnetic Fields.

Animals (Basel)

WG Environmental Health, Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Veterinärplatz 1, A-1210 Vienna, Austria.

Published: September 2021

Every year, approximately 3% of cats and dogs are lost. In addition to passive methods for identifying pets, radiofrequency tracking devices (TDs) are available. These TDs can track a pet's geographic position, which is transmitted by radio frequencies. The health risk to the animals from continuous exposure to radiofrequency electromagnetic fields (RF-EMFs) was reviewed. Fourteen out of twenty-one commercially available TDs use 2G, 3G, or 4G mobile networks, and the others work with public frequencies, WLAN, Bluetooth, etc. The exposure of pets to RF-EMFs was assessed, including ambient exposure (radios, TVs, and base stations of mobile networks), exposure from indoor devices (DECT, WLAN, Bluetooth, etc.), and the exposure from TDs. The exposure levels of the three areas were found to be distinctly below the International Commission on Non-Ionising Radiation Protection (ICNIRP) reference levels, which assure far-reaching protection from adverse health effects. The highest uncertainty regarding the exposure of pets was related to that caused by indoor RF-emitting devices using WLAN and DECT. This exposure can be limited considerably through a reduction in the exposure time and an increase in the distance between the animal and the RF-emitting device. Even though the total RF-EMF exposure level experienced by pets was found to be below the reference limits, recommendations were derived to reduce potential risks from exposure to TDs and indoor devices.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465301PMC
http://dx.doi.org/10.3390/ani11092721DOI Listing

Publication Analysis

Top Keywords

exposure
12
tracking devices
8
health risk
8
exposure radiofrequency
8
radiofrequency electromagnetic
8
electromagnetic fields
8
mobile networks
8
wlan bluetooth
8
bluetooth exposure
8
exposure pets
8

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Eisai Inc., Nutley, NJ, USA.

Background: Lecanemab is a humanized IgG1 monoclonal antibody that binds with high affinity to Aβ soluble protofibrils. In two clinical studies (phase 2, NCT01767311 and phase 3 ClarityAD, NCT03887455) in early Alzheimer's disease, lecanemab substantially reduced amyloid PET and significantly slowed clinical decline on multiple measures of cognition and function, including CDR-SB at 18 months. Models describing the change in amyloid PET and CDR-SB in response to lecanemab treatment were used to explore the impact of changing from the initial dosage regimen (10 mg/kg every 2 weeks [Q2W]) to a less intensive maintenance dosing regimen (10 mg/kg every 4 weeks [Q4W]) on clinical efficacy, and to explore the optimal duration of the initial dosing regimen.

View Article and Find Full Text PDF

Background: Although novel treatments for Alzheimer's disease (AD) have begun to show modest therapeutic effects, agents that target hallmark AD pathology and offer neuroprotection are desired. Erythropoietin (EPO) is a glycoprotein hormone with neuroprotective effects but is faced with challenges including limited brain uptake and increased hematopoietic side effects with long-term dosing. Therefore, EPO has been modified and bound to a chimeric transferrin receptor monoclonal antibody (cTfRMAb); the latter shuttles EPO past the blood-brain barrier (BBB) into brain parenchyma and reduces its plasma exposure and potential for side effects.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

AC Immune SA, Lausanne, Switzerland.

Background: The key advantage of active immunization is the induction of sustained, polyclonal antibody responses that are readily boosted by occasional immunizations. Recent clinical trial outcomes for monoclonal antibodies lecanemab and donanemab, establish the relevance of targeting pathological Abeta for clearing amyloid plaques in Alzheimer's disease. ACI-24.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Signant Health, Blue Bell, PA, USA.

Background: Clinical trial sponsors rely on research sites to identify and enroll appropriate study participants and to correctly and reliably assess symptom severity and function over the course of the trial. Low-recruiting sites represent a large financial and operational burden and may negatively impact trial success either by selecting inappropriate participants and/or high prevalence of data quality issues. We previously reported that >60% of sites in schizophrenia clinical trials recruited ≤5 participants.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Athira Pharma, Inc., Bothell, WA, USA.

Background: We have previously reported the neuroprotective effects of fosgonimeton in amyloid-β (Aβ)-driven preclinical models of Alzheimer's disease (AD). Fosgonimeton is an investigational small-molecule positive modulator of the neurotrophic hepatocyte growth factor (HGF) system, currently under investigation for mild-to-moderate AD (LIFT-AD; NCT04488419). Given the recent approvals of Aβ-targeting monoclonal antibodies (Aβ-mAbs) for the treatment of AD, and growing recognition that combination therapies may improve treatment outcomes, we sought to investigate the preclinical activity of fosgonimeton in the presence of Aβ-mAbs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!